

Get More with  
SINTA Insight

Go to Insight



MOLECULAR AND CELLULAR BIOMEDICAL SCIENCES (MCBS)

CELL AND BIOPHARMACEUTICAL INSTITUTE

P-ISSN : 25274384 &lt;&gt; E-ISSN : 25273442 Subject Area : Health, Science

1.71429  
Impact Factor486  
Google CitationsSinta 2  
Current  
Accreditation
[Google Scholar](#)
[Garuda](#)
[Website](#)
[Editor URL](#)

History Accreditation

2018 2019 2020 2021 2022 2023 2024 2025

[Garuda](#)
[Google Scholar](#)

### Molecular Docking of Citrus amblycarpa Active Compounds against FTO, Leptin, and Resistin Protein

Cell and BioPharmaceutical Institute [Molecular and Cellular Biomedical Sciences Vol 7, No 1 \(2023\) 38-46](#)

2023 [DOI: 10.21705/mcbs.v7i1.295](#) [Accred : Sinta 2](#)

### Association of ELM01 Genetic Polymorphism (rs741301) with the Progression of Diabetic Kidney Disease in Balinese Patients with Type 2 Diabetes Mellitus

Cell and BioPharmaceutical Institute [Molecular and Cellular Biomedical Sciences Vol 7, No 1 \(2023\) 47-51](#)

2023 [DOI: 10.21705/mcbs.v7i1.297](#) [Accred : Sinta 2](#)

### The Use of Cell-penetrating Peptide for Delivery of Recombinant Transcription Factor DNA into Primary Human Fibroblast

Cell and BioPharmaceutical Institute [Molecular and Cellular Biomedical Sciences Vol 7, No 1 \(2023\) 28-37](#)

2023 [DOI: 10.21705/mcbs.v7i1.279](#) [Accred : Sinta 2](#)

### Association between 25(OH)D3 Levels and the Presence of COVID-19 Symptoms


Cell and BioPharmaceutical Institute [Molecular and Cellular Biomedical Sciences Vol 7, No 1 \(2023\) 52-7](#)

2023 [DOI: 10.21705/mcbs.v7i1.306](#) [Accred : Sinta 2](#)

### Allogeneic Mesenchymal Stem Cells and Its Conditioned Medium as a Potential Adjuvant Therapy for COVID-19

Cell and BioPharmaceutical Institute [Molecular and Cellular Biomedical Sciences Vol 7, No](#)

Citation Per Year By Google Scholar



Journal By Google Scholar

	All	Since 2018
Citation	486	482
h-index	10	10
i10-index	12	12

# Molecular and Cellular Biomedical Sciences

HOME ABOUT LOGIN REGISTER SEARCH CURRENT ARCHIVES ANNOUNCEMENTS ARTICLE IN PRESS

Home > Archives > **Vol 3, No 1 (2019)**

Vol 3, No 1 (2019)

## Front and Back Matters

View or download the Front and Back Matters

PDF

## Table of Contents

### Research Article

**Investigation on Cell Surface Markers of Dental Pulp Stem Cell Isolated from Impacted Third Molar Based on International Society for Cellular Therapy Proposed Mesenchymal Stem Cell Markers**

Ferry Sandra, Janti Sudiono, Yohana Feter, Nadhia Sari Afiana, Jessica Nathalia Chandra, Kharima Abdullah, Jasmine Shafira, Angliana Chouw

PDF

1-6

PDF

**John Cunningham Virus T-Antigen Expression on Mild and Severe Dysplasia Adenomatous Polyp, Low and High Grade Adenocarcinoma of The Colon**

Dyonesia Ary Harjanti, Cyprianus Murtono, Kidyarto Suryawinata, Angelina Halim, Michelle Felicia Wiryokusuma, Timotius Benedict Djitro

PDF

7-12

PDF

**The Relationship of Hemoglobin, Interleukin-10 and Tumor Necrosis Factor Alpha Levels In Asymptomatic Malaria Patients in Trenggalek, Jawa Timur, Indonesia**

Arif Rahman Nurdianto, Heny Arwati, Yoes Prijatna Dachlan, Dyah Ayu Febiyanti

PDF

13-6

PDF

**Microbial Patterns and Antimicrobial Susceptibility on Pediatric Patients with Pressure Ulcers**

Deryne Anggia Paramita, Khairina Nasution, Nova Zairina Lubis

PDF

17-21

PDF

**Soymilk Formula Increases Estrogen and Reduces Testosterone Level in Male Infant White Wistar Rats**

Eveline Margo, Wimpie Pangkahila, I Gusti Made Aman

PDF

22-5

PDF

**The Effect of Human Platelet-Rich Plasma and L-Ascorbic Acid on Morphology, Proliferation, and Chondrogenesis Ability towards Human Adipose-Derived Stem Cells**

Imam Rosadi, Karina Karina, Iis Rosliana, Siti Sobariah, Irsyah Afini, Tias Widayastuti, Anggraini Barlian

PDF

26-33

PDF

**Cytotoxic Activity of Methoxy-4' amino Chalcone Derivatives Against Leukemia Cell Lines**

Arina Novilla, Mustofa Mustofa, Indwiani Astuti, Jumina Jumina, Hery Suwito

PDF

34-41

PDF

**Correlation Between Pyridoxal 5'-Phosphate Level And Valproic Acid In Epilepsy Children**

I Gusti Ngurah Made Suwarba, Ni Putu Yunik Novayanti, I Gusti Lanang Sidiartha, Dewi Sutriani Mahalini

PDF

42-7

PDF

**Correlation between the Inflammation Factors and Intima-Media Thickness in Patients with End-Stage Renal Disease (ESRD) on Regular Hemodialysis**

Lestariningsih Lestariningsih, Wiguno Projosudjadi, Mochamad Sya'bani, Suharyo Hadisaputra

PDF

48-53

PDF

**Plasma Level of Umbilical Cord Hemeoxygenase-1 (HO-1) and Neonatal Outcome in Early Onset and Late Onset Severe Preeclampsia**

Muhammad Ilham Aldika Akbar, Indah Mayang Sari, Ernawati Ernawati, Aditiawarman Aditiawarman

PDF


54-9

PDF

Indexed by:



Cell and BioPharmaceutical Institute



### USER

Username

Password

Remember me

Login

### Indexation Page

View Website Statistics

80062180

### CURRENT ISSUE

ATOM 1.0  
RSS 2.0  
RSS 1.0

OPEN JOURNAL SYSTEMS

# Molecular and Cellular Biomedical Sciences

[HOME](#) | [ABOUT](#) | [LOGIN](#) | [REGISTER](#) | [SEARCH](#) | [CURRENT](#) | [ARCHIVES](#) | [ANNOUNCEMENTS](#) | [ARTICLE IN PRESS](#)

[Home](#) > [About the Journal](#) > **Editorial Team**

## Editorial Team

### Editor in Chief

**Prof. Gerard Pals**, Department of Clinical Genetics, Amsterdam University Medical Center, Netherlands

### Board of Editors

**Prof. Ahmad Faried**, Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran, Indonesia  
**Prof. Anak Jamaroon**, Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Thailand  
**Dr. Anna Meiliana**, Postgraduate Program in Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia  
**Dr. Bin Ren**, Department of Molecular and Vascular Pathobiology, University of Alabama at Birmingham, United States  
**Dr. Ines Atmosukarto**, College of Medicine, Biology & Environment, Australian National University, Australia  
**Prof. Mutsumi Miyauchi**, Department of Oral and Maxillofacial Pathobiology, Institute of Biomedical and Health Sciences, Hiroshima University, Japan  
**Prof. Thai Yen Ling**, Department of Pharmacology, College of Medicine, National Taiwan University, Taiwan  
**Dr. Wahyu Widowati**, Department of Biology, Faculty of Medicine, Maranatha Christian University, Indonesia

### Board of Reviewers

**Prof. Akihiro Shimosaka**, Hematology Institute, Peking Union Medical College, China  
**Dr. Ditha Diana**, Anatomic Pathology Laboratory, Prodia Clinical Laboratory, Indonesia  
**Prof. Hee Young Shin**, Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, South Korea  
**Prof. Hiroyuki Kumamoto**, Division of Oral Pathology, Department of Oral Medicine and Surgery, Graduate School of Dentistry, Tohoku University, Japan  
**Prof. Irawan Satriotomo**, Center for Translational Research in Neurodegenerative Disease, University of Florida, United States  
**Dr. Laifa Annisa Hendarmin**, Section of Biology, Faculty of Medicine and Health Sciences, Syarif Hidayatullah State Islamic University, Indonesia  
**Prof. Yen Hua Huang**, Department of Biochemistry and Molecular Cell Biology, Graduate Institute of Medical Sciences, Taipei Medical University, Taiwan  
**Prof. Yudi Her Oktaviono**, Department of Cardiology and Vascular Medicine, Faculty of Medicine / Dr. Soetomo Hospital, Universitas Airlangga, Indonesia

Indexed by:



### Cell and BioPharmaceutical Institute



### USER

Username

Password

Remember me

### Indexation Page

**View Website Statistics**

**80062198**

[OPEN JOURNAL SYSTEMS](#)

## RESEARCH ARTICLE

MCBS

Mol Cell Biomed Sci. 2019; 3(1): 54-9  
DOI: 10.21705/mcbs.v3i1.57

## Plasma Level of Umbilical Cord Hemeoxygenase-1 (HO-1) and Neonatal Outcome in Early Onset and Late Onset Severe Preeclampsia

Muhammad Ilham Aldika Akbar<sup>1,2</sup>, Indah Mayang Sari<sup>1</sup>, Ernawati<sup>1,2</sup>, Aditiawarman<sup>1</sup><sup>1</sup>Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Hospital, Surabaya, Indonesia<sup>2</sup>Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Airlangga/Universitas Airlangga Hospital, Surabaya, Indonesia

**Background:** Many studies had discovered that early onset severe preeclampsia (EO-PE) has worst maternal and neonatal outcome compared to late-onset type (LO-PE), related to its placental involvement. Severe preeclampsia was defined as newly onset severe hypertension developed after 20 weeks gestation in previously normal blood pressure women, with coexistence of proteinuria, or maternal organ or uteroplacental dysfunction. Hemeoxygenase-1 (HO-1) is an enzyme with multiple effect which is protective to pregnancy.

**Materials and Methods:** The total study subjects were 40 pregnant women consisted of 10 EO-PE, 10 normal early onset pregnancy (EO-NP), 10 LO-PE, and 10 normal late onset pregnancy (LO-NP). As much as 5 cc of plasma from umbilical cord was taken as soon as the baby was born, and the HO-1 level was examined by enzyme-linked immunosorbent assay (ELISA). The primary outcome were umbilical cord HO-1 level and neonatal composite morbidity (low Apgar score, low birthweight, length of stay >5 day, respiratory distress syndrome, jaundice and neonatal death).

**Results:** The plasma level of HO-1 in EO-PE subjects were lower than EO-NP ( $0.96 \pm 0.37$  ng/mL vs.  $2.43 \pm 0.58$  ng/mL,  $p < 0.001$ ). There were no significant differences in the level of HO-1 in LO-PE and LO-NP ( $2.18 \pm 1.07$  ng/mL vs.  $3.02 \pm 0.64$  ng/mL,  $p = 0.277$ ). Plasma level of umbilical cord HO-1 of EO-PE patients was lower compared to LO-PE ( $0.96 \pm 0.37$  ng/mL vs.  $2.18 \pm 1.07$  ng/mL,  $p = 0.034$ ). Neonatal outcome of EO-PE was worse than EO-NP ( $p = 0.033$ ), and LO-PE ( $p = 0.003$ ), while in LO-PE did not different with LO-NP ( $p = 0.211$ ).

**Conclusion:** EO-PE is associated with lower plasma umbilical cord level of HO-1 and worse neonatal outcome compared to LO-PE. This indicating abnormal placental blood vessel development, placental ischemia in EO-PE, lead to reduced uteroplacental perfusion and significantly worse neonatal outcome compared to LO-PE.

**Keywords:** severe preeclampsia, early onset preeclampsia, late onset preeclampsia, hemeoxygenase-1

Date of submission: January 8, 2019

Last Revised: February 11, 2019

Accepted for publication: February 12, 2019

**Corresponding Author:**Muhammad Ilham Aldika Akbar  
Department of Obstetric and Gynecology  
Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Hospital  
Jl. Airlangga No.4-6, Surabaya, Indonesia  
E-mail: muhammad-i-a-a@fk.unair.ac.idCell and  
Biopharmaceutical  
Institute

## Introduction

Preeclampsia is a major contributor of maternal and fetal morbidity and mortality worldwide.<sup>1</sup> Recently preeclampsia is classified based on the onset of the disease into early onset preeclampsia (EO-PE) <34 week gestation and late onset preeclampsia (LO-PE) >34 week. These two type of preeclampsia were suspected to have a different pathophysiology, clinical manifestation and outcome.<sup>2,3</sup> EO-PE occurs mainly due to abnormal placentation which can be caused by reduced of cell protective factors (such as nitrite, hemeoxygenase-1 (HO-1)), or oxidative stress, genetic, environmental and immunological factors.<sup>2,4</sup> Whereas LO-PE is associated with underlying maternal disease coexisted in pregnancy, rather than abnormal placental development.<sup>2,3</sup>

Earlier study mentioned that there were two protective pathways in pregnancy, namely the hemeoxygenase-carbon monoxide/HO-CO pathway and the cystathionine- $\gamma$ -lyase pathway.<sup>4</sup> Deficiency in this protective pathway will lead to abnormal development of placental vascular system, eventually ended in preeclampsia. HO-1 is an enzyme that degrades free heme to produce a number of carbon monoxide (CO), iron (Fe<sup>2+</sup>), and biliverdin through cytochrome P450 reductase (CPR).<sup>4,5</sup> The *in vivo* and *in vitro* studies showed that HO-1 functions as a cytoprotector by degrading free heme which is highly reactive cytotoxic substance, and produces CO as a mediator of inhibiting inflammatory and apoptotic processes.<sup>4</sup> HO-1 is expressed in the syncytiotrophoblast and involved in placental cell protection and relaxation of blood vessels during pregnancy.<sup>6</sup> In preeclampsia, there is a disruption of regulation and development of placental blood vessels which is thought to be caused by reduced expression of HO-1 in the placenta. In this study we measure plasma HO-1 levels of umbilical cord and fetal outcome in EO-PE, LO-PE and normal pregnancy, to determine the role of placental HO-1 in the pathogenesis of preeclampsia and its relation to the clinical outcome.

## Materials and methods

This is a comparative analytic observational study with cross sectional method, comparing HO-1 levels of umbilical cord blood of newborns and neonatal outcome in EO-PE, LO-PE and control groups (early onset-normal pregnancy (EO-NP) and late onset-normal pregnancy (LO-NP)). This study was conducted in Dr. Soetomo General Hospital, Airlangga University Hospital and Dr. M. Soewandhi Hospital,

Surabaya, during December 2016 - February 2017. Inclusion criteria were pregnant women with severe preeclampsia and normal pregnant women >20 weeks. Severe preeclampsia was diagnosed based on the International Society for The Study of Hypertension in Pregnancy (ISSHP) classification: severe hypertension (blood pressure >160/110 mmHg) developing after 20 weeks gestation and the coexistence of one of this condition (proteinuria, maternal organ dysfunction, or uteroplacental dysfunction). Maternal organ dysfunction involved: renal insufficiency (serum creatinine >90  $\mu$ mol/L), liver involvement (elevated transaminase, severe right upper quadrant or epigastric pain), neurological complication (eclampsia, altered mental status, blindness, stroke, hyperreflexia, *etc.*), and haematological complication.<sup>7</sup> While the exclusion criteria were pregnant women who had an co-existing diseases (such as metabolic diseases, systemic diseases, autoimmune, gynecological infections and tumors), refuse to be involved in the research, smokers and multiple pregnancies. The sample size of each group was 10 patients, based on previous related study.<sup>8</sup> The sampling in severe preeclampsia groups was done by consecutive sampling method, while in control group was carried out using a simple randomized method. As much as 5 cc of plasma umbilical cord was taken as soon as the baby is born and then HO-1 levels were examined by enzyme-linked immunosorbent assay (ELISA) (StressXpress ELISA kit, StressMarq Biosciences Inc, Victoria, Canada). Babies were followed until they were discharged from the hospital, and neonatal composite morbidity was assessed. Neonatal composite morbidity consisted of: Apgar score <3, baby birthweight <2000 gram, neonatal length of stay >5 days, respiratory distress syndrome, jaundice and neonatal death. Apgar score was measured of the fetal clinical performance on 1<sup>st</sup> minute, based on appearance, pulse, grimace, activity, and respiratory.<sup>9</sup> Respiratory distress syndrome was diagnosed based on clinical sign of dyspnea, grunting, tachypnea (respiratory rate >60x/minutes), chest indrawing, cyanosis, laboratory, and chest-x ray. Data was analyzed using Anova test, post hoc Tamhane test, Kruskal Wallis test, Fisher exact test, and eta association test to evaluate the different and the associatioan between each variable (SPSS 23, SPSS Inc., Illinois, USA).

## Results

### *Characteristics of Research Samples*

Based on the data in Table 1, we found a significant differences in the age of the patients between EO-PE *vs.*

**Table 1. General characteristics.**

Variables	EO-NP (n=10)	EO-PE (n=10)	LO-NP (n=10)	LO-PE (n=10)
	n / Mean±SD / Median (range)	n / Mean±SD / Median (range)	n / Mean±SD / Median (range)	n / Mean±SD / Median (range)
<b>Age (years)<sup>1</sup></b>	<b>23.1 (4.82)<sup>a</sup></b>	<b>36.9 (3.04)<sup>a</sup></b>	<b>24.8 (3.65)</b>	<b>30.8 (6.89)</b>
<20	3	0	0	1
20-34	7	2	10	5
≥35	0	8	0	4
<b>Gravida<sup>2</sup></b>	<b>1 (1-2)<sup>b</sup></b>	<b>2 (1-4)<sup>b, c</sup></b>	<b>2 (1-3)</b>	<b>1 (1-3)<sup>c</sup></b>
Primigravida	7	2	3	6
Multigravida	3	8	7	4
<b>UK (week)<sup>3</sup></b>	<b>33 (29-33)</b>	<b>33 (26-33)</b>	<b>38 (35-40)</b>	<b>37 (35-39)</b>
<34	10	10	0	0
> 34	0	0	10	10
<b>BMI (kg/m<sup>2</sup>)<sup>2</sup></b>	<b>24.7 (22.3-36.8)</b>	<b>24.6 (22.4-37.2)</b>	<b>23.9 (21.3-34.2)<sup>d</sup></b>	<b>32.8 (23.8-40.1)<sup>d</sup></b>
Normal	7	4	6	1
Overweight	0	2	2	1
Obesity I	2	3	2	6
Obesity II	1	1	0	1
Obesity III	0	0	0	1
<b>Type of Delivery<sup>2</sup></b>				
SC	1	8	4	4
Spontaneous	9	2	5	4
Extraction Vacuum	0	0	1	2
<b>Maternal Complication<sup>3</sup></b>				
Lung Edema	0	2	0	0
Eclampsia	0	2	0	1
HELLP Syndrome	0	1	0	0

\*Significant value  $p < 0.05$ . <sup>1</sup>One way Anova, <sup>2</sup>Kruskal-Wallis, <sup>3</sup>Mann-Whitney. a: comparison between a-a ( $p < 0.001$ ); b: comparison between b-b ( $p = 0.012$ ); c: comparison between c-c ( $p = 0.041$ ); d: comparison between d-d ( $p = 0.010$ ).

EO-NP ( $p < 0.001$ ), the number of gravidity between the EO-PE vs. EO-NP ( $p = 0.012$ ) and EO-PE vs. LO-PE ( $p = 0.041$ ). BMI between LO-PE vs. LO-NP was also significantly different ( $p = 0.010$ ), while other parameters did not show any significant different.


#### **Plasma Umbilical Cord Hemeoxygenase-1 (HO-1)**

Plasma umbilical cord HO-1 level of EO-PE ( $0.96 \pm 0.37$  ng/mL) was significantly lower compared to EO-NP ( $2.43 \pm 0.58$  ng/mL;  $p < 0.001$ ), and LO-PE ( $2.18 \pm 1.07$  ng/mL;  $p = 0.034$ ). While plasma umbilical cord HO-1 in LO-PE was not different with LO-NP, although tend to be lower (Figure 1, Table 2). The lowest HO-1 level was found in EO-PE group ( $0.55$  ng/mL), and the highest was in LO-NP ( $3.86$  ng/mL).

#### **Neonatal Outcome**

In term of neonatal outcome, there were significant differences in Apgar scores ( $p = 0.008$ ), baby birth weight ( $p < 0.001$ ), and length of stay ( $p = 0.001$ ), between EO-PE and LO-PE (Table 3). And the length of stay of LO-PE was longer than LO-NP (3 vs. 2.5;  $p = 0.038$ ). But there were no significant differences in apgar score and baby birth weight between EO-PE vs. EO-NP, and LO-PE vs. LO-NP.

The assessment of neonatal composite morbidity includes low Apgar score (Apgar score  $< 3$ ), low birth weight (birth weight  $< 2000$  grams), length of stay  $> 5$  days, complications in newborns at hospital, such as respiratory distress syndrome, neonatal jaundice, and neonatal death. Any occurrence of these variable on baby indicating



**Figure 1. Plasma umbilical cord HO-1 level in EO-NP, EO-PE, LO-NP and LO-PE.**

positive neonatal composite morbidity. The EO-PE had more neonatal composite morbidity than LO-PE and EO-NP, indicating that the outcomes of newborns in EO-PE was worse compared to the LO-PE ( $p=0.003$ ) and EO-NP ( $p=0.033$ ). While the composite morbidity in LO-PE was not different with LO-NP ( $p=0.211$ ) (Table 4). Based on further statistical analysis using the contingency coefficient test, there was a significant positive correlation of neonatal composite morbidity with EO-PE, with medium strength ( $p=0.010$ ,  $r=0.500$ ). It means that the occurrence of EO-PE increase the risk of composite neonatal morbidity.

Based on the eta association test, a positive correlation was found to be very strong between plasma umbilical cord HO-1 level and neonatal composite morbidity ( $p<0.001$ ,  $r=0.974$ ). Low levels of plasma umbilical cord HO-1 correlate with worse neonatal outcome.

## Discussion

This study support the hypothesis that EO-PE has a different pathogenesis compared to LO-PE, which is involvement of

placenta. Plasma umbilical cord HO-1 can represent the level of placental HO-1, and the lower placental HO-1 is correlated with abnormal placental blood vessel development and inadequate vascularization. Our study reveal that in EO-PE group the plasma umbilical cord HO-1 level was lower than LO-PE and EO-NP. While HO-1 level in LO-PE was not different with LO-NP. Many studies (animal model and human) had already proven that deficiency of placental HO-1 were correlated with smaller spiral arteries, inadequate placental vascularization, different placental angiogenic profile, and significantly higher blood pressure, which is the main feature of placental preeclampsia.<sup>10-12</sup> Placental tissue of preeclampsia pregnant women has already proven to have a lower expression of HO-1, lower mRNA HO-1, and lower HO-1 protein level compared to normal pregnancy.<sup>6,13,14</sup>

Deficiency HO-1 may also shift the balance toward anti angiogenesis dominant, which result in endothelial cell damage through its relation with soluble FMS like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng).<sup>15</sup> Cudmore, *et al.*, showed that induction of HO-1 in human umbilical endothelial vein endothelial cells (HUVECs) inhibit the release of sFlt-1 and sEng.<sup>16,17</sup> Circulating sFlt-1 and sEng are the two main factors in the development of clinical syndrome of preeclampsia. Our study result indicating that in EO-PE (but not in LO-PE) the placenta was involved, reflected by the lower level of plasma HO-1. This placental vascular involvement in EO-PE will decrease uteroplacental blood flow, lead to uteroplacental insufficiency and correlate with poor pregnancy outcome.<sup>18</sup> While LO-PE is associated with normal placental vascular development, normal uteroplacental perfusion, normal placental volume and better pregnancy outcome.<sup>2,19</sup> Our study support this hypothesis with the finding that neonatal outcome and composite morbidity in EO-PE was worse compare to the LO-PE and EO-NP. Baby delivered from EO-PE woman had lower Apgar score, lower birth weight, and longer length of stay compared to LO-PE. Since neonatal morbidity also

**Table 2. Plasma levels of umbilical cord HO-1.**

Variable	Group	Early Onset	Late Onset	p-value
		Mean±SD (ng/mL)	Mean±SD (ng/mL)	
Hemeoxygenase -1 (HO-1)	Control	2.43±0.58	3.02±0.64	-
	Severe Preeclampsia	0.96±0.37	2.18±1.07	0.034*
	p-value	<0.001*	0.277	-

\*Significant value  $p<0.05$ , tested with ANOVA.

**Table 3. Neonatal outcome.**

Variable	Group	Early Onset	Late Onset	p-value
		Median (range)	Median (range)	
Apgar score <sup>2</sup>	Control	6 (6-8)	8 (7-8)	-
	Severe Preeclampsia	5 (3-8)	7.5 (6-8)	0.008 *
	p-value	0.149	0.313	-
Birth Weight <sup>3</sup> (grams)	Control	2095 (1300-2300)	3145 (2590-3660)	-
	Severe Preeclampsia	1900 (1000-2240)	2985 (2510-3220)	<0.001 *
	p-value	0.495	0.241	-
Length of stay <sup>2</sup> (days)	Control	7.5 (2-28)	2.5 (1-3)	-
	Severe Preeclampsia	17 (5-30)	3 (2-7)	0.001 *
	p-value	0.079	0.038 *	-

\*Significant value  $p < 0.05$ . <sup>1</sup>One way Anova, <sup>2</sup>Kruskal-Wallis, <sup>3</sup>Mann-Whitney.

closely related to gestational age at the time of delivery, more severe form of EO-PE often necessitate iatrogenic preterm delivery, which result in prematurity. Prematurity will directly increase neonatal morbidity (respiratory distress syndrome, neonatal jaundice) and mortality. Our finding is in line with many recent studies which stated that neonatal outcome in EO-PE was worse compared to LO-PE.<sup>19-21</sup> And also the neonatal outcome in LO-PE was not different with the LO-NP, indicating relatively normal placental development and uteroplacental perfusion in this type of preeclampsia.

This study also reveal a strong correlation between plasma umbilical cord HO-1 level with neonatal composite morbidity. It means that low umbilical cord HO-1 level is correlated with poor neonatal outcome. Many studies had proven that deficiency HO-1 in placenta and circulation was correlated with poor pregnancy outcome, such as miscarriage, intra uterine growth restriction, intra uterine fetal death, and preterm labour.<sup>22-27</sup> This might be explained by an unopposed free fetal heme on deficient HO-1 placenta

that stimulates cell damage, subsequently lead to abnormal placentation.<sup>27</sup> But as far as we know, this was the first study to evaluate the relationship between placental HO-1 and neonatal outcome. The strong relationship between low level of placental plasma HO-1 and neonatal composite morbidity (especially in EO-PE) could provide clue about the role of placental HO-1 deficiency in the development of more severe type of preeclampsia with abnormal placental development and poor neonatal outcome. Deficiency of placental HO-1 was correlated with increased level of sFlt-1 and sEng, which associated with clinical severity of preeclampsia.<sup>4</sup> Study on animal model showed that induction of HO-1 inhibit sFlt-1 and sEng level, increased VEGF level, improved endothelial function, and decreased blood pressure.<sup>16,17,28</sup>

Our study result indicate that in the future, HO-1 inducer (statin) may be used to protect the normal placental vascular development in pregnancy, prevent placental insufficiency syndrome such as preeclampsia (especially the early type), and improve the neonatal outcome.

**Table 4. Composite neonatal morbidity.**

Variables	EO-NP	EO-PE	LO-NP	LO-PE
Apgar score <3	0	2	0	0
Birth Weight <2000 grams	2	5	0	0
Length of Stay >5 days	5	7	0	2
Respiratory Distress Syndrome	1	3	0	0
Neonatal Jaundice	2	7	0	3
Neonatal Death	1	3	0	0
Neonatal Composite Morbidity	5	10	0	3



## Conclusion

This study reveal that defficiency placental HO-1 is correlated with poor neonatal outcome (especially in EO-PE) via abnormal placental vascular development. HO-1 inducer (statin) should be consider as a new approach in the future to protect vascular placental insufficiency, prevent subsequent preeclampsia syndrome, and improve neonatal outcome.

## References

1. Wang K, Ahmad S, Cai M, Rennie J, Fujisawa T, Crispi F, *et al.* Dysregulation of hydrogen sulfide producing enzyme cystathioninelyase contributes to maternal hypertension and placental abnormalities in preeclampsia. *Circulation*. 2013; 127(25): 2514-22.
2. Sulistyowati S. Early and Late Onset Preeclampsia: What did really matter?. *J Gynecol Women's Health*. 2017; 5(4): 555670. doi: 10.19080/jgwh.2017.05.555670.
3. Chaiworapongsa T, Chaemsaitong P, Yeo L, Romero R. Preeclampsia part 1: current understand of its pathophysiology. *Nat Rev Nephrol*. 2014; 10: 466-80.
4. Ahmed A, Ramma W. Unravelling the theories of preeclampsia: are the protective pathways the new paradigm. *Br J Pharmacol*. 2015; 172(6): 1574-86.
5. Zhao H, Wong RJ, Kalish FS, Nayak NR, Stevenson DK. Effect of heme oxygenase-1 deficiency on placental development. *Placenta*. 2009; 30(10): 861-8.
6. Ahmed A, Rahman M, Zhang X, Acevedo CH, Nijjar S, Rushton I, *et al.* Induction of placental heme oxygenase-1 is protective against TNF $\alpha$ -induced cytotoxicity and promotes vessel relaxation. *Mol Med*. 2000; 6(5): 391-409.
7. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, *et al.* The classification, diagnosis, and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. *Pregnancy Hypertens*. 2014; 4(2): 97-104.
8. Vitaratos N, Papakonstantinou K, Deliveliotou A, Economou E, Panoulis C, Hassiakos D, *et al.* Antepartum and postpartum serum heme oxygenase-1 levels in preeclamptic and normotensive pregnant women. *In Vivo*. 2011; 25(3): 445-50.
9. Committee on Obstetric Practice American Academy of Pediatrics - Committee on Fetus and Newborn. Committee Opinion No. 644: The Apgar Score. *Obstet Gynecol*. 2015; 126(4): e52-5.
10. Mclean M, Bowman M, Clifton V, Smith R, Grossman AB. Expression of the heme oxygenase – carbon monoxide signalling system in human placenta. *J Clin Endocrinol Metab*. 2000; 85(6): 2345-9.
11. Zhao H, Wong RJ, Doyle TC, Nayak N, Vreman HJ, Contag CH, *et al.* Regulation of maternal and fetal hemodynamics by heme oxygenase in mice. *Biol Reprod*. 2008; 78(4): 744-51.
12. Zhao H, Azuma J, Kalish F, Wong RJ, Stevenson DK. Maternal heme oxygenase 1 regulates placental vasculature development via angiogenic factors in mice. *Biol Reprod*. 2011; 85(5): 1005-12.
13. Padmini E, Lavanya D. HIF-1 $\alpha$ , TNF- $\alpha$ , and HO-1 modulation in placental explants during preeclampsia. *Int J Res Chem Environ*. 2014; 4(2): 85-92.
14. Farina A, Sekizawa A, De Sanctis P, Purwosunu Y, Okai T, Cha DH. Gene expression in chorionic villous samples at 11 weeks gestation from women destined to develop preeclampsia. *Prenat Diagn*. 2008; 28(10): 956-61.
15. Levytska K, Kingdom J, Baczyk D, Drewlo S. Heme oxygenase-1 in placental development and pathology. *Placenta*. 2013; 34(4): 291-8.
16. Cudemore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, *et al.* Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. *Circulation*. 2007; 115(13): 1789-97.
17. Cudemore MJ, Ramma W, Cai M, Fujisawa T, Ahmad S, Al-Ani B, *et al.* Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta. *Am J Obstet Gynecol* 2012; 206(3): 253.e10-5.
18. Than NG, Vaisbuch, E, Kim CJ. Early-onset preeclampsia and HELLP Syndrome: an Overview. In: *Handbook of Growth Monitoring in Health and Disease*. New York: Springer Science; 2011. p.1867-91.
19. Madazli R, Yuksel MA, Imamoglu M, Tuten A, Oncul M, Aydin B, *et al.* Comparison of clinical and perinatal outcomes in early and late onset preeclampsia. *Arch Gynecol Obstet*. 2014; 290(1): 53-7.
20. Bozdag H, Ogutcuoglu FBG, Guzin K, Kabaca Kilic SR, Duran EA, Topdagi Aydin I, *et al.* The frequency and fetomaternal outcomes of early and late onset preeclampsia: The experience of a single tertiary center in bustling metropolis of Turkey; Istanbul. *Med Med J*. 2015; 30(4): 163-9.
21. Aldika Akbar MI, Herdiyantini M, Aryananda RA, Cininta N, Wardhana MP, Gumilar KE, *et al.* Serum heme oxygenase 1 (HO-1), soluble FMS like tyrosine kinase (sFlt-1) level, and neonatal outcome in early onset, late onset preeclampsia and normal pregnancy. *Hypertens Pregnancy*. 2018; 37(4): 175-81.
22. Maroti Z, Katona M, Orvos H, Nemeth I, Farkas I, Turi S. Heme oxygenase-1 expression in premature and mature neonates during the first week of life. *Eur J Pediatr*. 2007; 166(10): 1033-8.
23. Barber A, Robson SC, Myatt L, Bulmer JN, Lyall F. Heme oxygenase expression in human placenta and placenta bed: reduced expression of placenta endothelial HO-2 in preeclampsia and fetal growth restriction. *FASEB J*. 2001; 15(7): 1158-68.
24. Dennerly PA. Signaling fuction of heme oxygenase proteins. *Antioxid Redox Signal*. 2014; 20(11): 1743-53.
25. Gonzalez S, Perez MJ, Perazzo JC, Tomaro MI. Antioxidant role of heme oxygenase-1 in prehepatic portal hypertensive rats. *World J Gastroenterol*. 2006; 12(26): 4149-55.
26. Wong RJ, Zhao H, Stevenson DK. A deficiency in heme oxygenase-1 induces foetal growth restriction by placental vasculature defects. *Acta Paediatr*. 2012; 101(8): 827-34.
27. Zenclussen ML, Linzke N, Schumacher A, Fest S, Meyer N, Cassalis PA, *et al.* Heme oxygenase-1 is critically involved in placentation, spiral artery remodeling, and blood pressure regulation during murine pregnancy. *Front Pharmacol*. 2015; 5: 291. doi: 10.3389/fphar.2014.00291.
28. George EM, Colson D, Dixon J, Palei AC, Granger JP. Heme oxygenase-1 attenuates hypoxia-induced sFlt-1 and oxidative stress in placental villi through its metabolic products Co and bilirubin. *Int J Hypertens*. 2012; 2012: 486053. doi: 10.1155/2012/486053.